Home LiteratureArticle Details
PMID: 11586098 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.

American journal of clinical oncology ·Vol. 24 ·No. 5 ·2001-10-00 ·Pages 467-72

Evans SM, Hahn SM, Magarelli DP, Koch CJ

Abstract

We evaluated the levels and distribution of hypoxia in 31 human tumors using fluorescent immunohistochemical detection of binding by the 2-nitroimidazole, EF5. Hypoxia was found to be a heterogeneous property of human tumors. Necrosis was usually found adjacent to the highest level of binding in an individual patient's tumor. However, hypoxia often occurred without necrosis. In the group of tumors studied, the most common relationship between blood vessels (PECAM/CD31) and EF5 staining was consistent with diffusion-limited hypoxia; acute hypoxia occurred infrequently. Within a given patient's tumor, there was an inverse correlation between regions of proliferation (Ki-67) and regions of hypoxia. Again, however, when these parameters were examined in a group of patients, the absence of proliferation did not predict the presence of hypoxia. The relationships between hypoxia and other biologic endpoints are complex, but, within a given tumor's spatial relationships, they are in accord with known physiologic principles. Thus, our data emphasize that the relationships between hypoxia and other biologic parameters vary between patients. Necrosis, proliferation, and blood vessel distribution cannot predict the level or presence of hypoxia in an individual patient's tumor.

MeSH Terms
Antineoplastic Agents Cell Division Cell Hypoxia Clinical Trials, Phase I as Topic Etanidazole/analogs & derivatives,metabolism Humans Hydrocarbons, Fluorinated/metabolism Immunohistochemistry Indicators and Reagents Necrosis Neoplasms/blood supply,metabolism,pathology Neovascularization, Pathologic
Chemicals
Antineoplastic Agents Hydrocarbons, Fluorinated Indicators and Reagents Etanidazole 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Evans S M
University of Pennsylvania, School of Medicine, Department of Radiation Oncology, Philadelphia, Pennsylvania 19104, USA.
Hahn S M
Magarelli D P
Koch C J
Article Info
Journal
American journal of clinical oncology
Abbr.
Am J Clin Oncol
ISSN
0277-3732
Published
2001-10-00
Pages
467-72
Language
English
Region
United States
NLM ID
8207754
Subset
IM
Grants
NCI NIH HHS · 1RO1-CA 75285 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com